United Therapeutics Corp (NASDAQ:UTHR) reported better-than-expected earnings for the fourth quarter on Wednesday.
The company posted quarterly earnings of $7.70 per share which beat the analyst consensus estimate of $7.09 per share. The company reported quarterly sales of $790.200 million which missed the analyst consensus estimate of $813.077 million.
“As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation and excellence fuels our mission,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “Looking ahead, our ADVANCE OUTCOMES and TETON-1 clinical programs are on the cusp of unveiling pivotal data that could unlock significant new treatment options for patients, …